4-(hydroxymethyl)phenyl isobutyrate | 70362-64-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚酯
• 英文名称: 4-(hydroxymethyl)phenyl isobutyrate
• 英文别名: 4-(isobutyryloxy)benzyl alcohol；4-(Hydroxymethyl)phenyl 2-methylpropanoate；[4-(hydroxymethyl)phenyl] 2-methylpropanoate
• CAS: 70362-64-0
• 化学式: C₁₁H₁₄O₃
• mdl: MFCD11616914
• 分子量: 194.23
• InChiKey: RWFXLBNAVZAHHO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  14
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.363
• 拓扑面积：
  46.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-(hydroxymethyl)phenyl isobutyrate 在 咪唑 、 Tris buffer 、 碘 、 三苯基膦 作用下， 以 乙醚 、 乙腈 为溶剂， 反应 5.5h， 生成
  参考文献：
  名称：

  Acyloxyaryl prodrugs of oligonucleoside phosphorothioates

  摘要：

  Improved design, synthesis, and evaluation of an oligonucleotide prodrug is described. Copyright (C) 1996 Elsevier Science Ltd

  DOI：

  10.1016/0960-894x(96)00332-0
• 作为产物：
  描述：

  4-甲酰基苯基2-甲基丙酸酯 在 sodium tetrahydroborate 作用下， 以 四氢呋喃 为溶剂， 以83%的产率得到4-(hydroxymethyl)phenyl isobutyrate
  参考文献：
  名称：

  Formulating a new basis for the treatment against botulinum neurotoxin intoxication: 3,4-Diaminopyridine prodrug design and characterization

  摘要：

  Botulism is a disease characterized by neuromuscular paralysis and is produced from botulinum neurotoxins (BoNTs) found within the Gram positive bacterium Clostridium botulinum. This bacteria produces the most deadliest toxin known, with lethal doses as low as 1 ng/kg. Due to the relative ease of production and transport, the use of these agents as potential bioterrorist weapons has become of utmost concern. No small molecule therapies against BoNT intoxication have been approved to date. However, 3,4-diaminopyridine (3,4-DAP), a potent reversible inhibitor of voltage-gated potassium channels, is an effective cholinergic agonist used in the treatment of neuromuscular degenerative disorders that require cholinergic enhancement. 3,4-DAP has also been shown to facilitate recovery of neuromuscular action potential post botulinum intoxication by blocking K(+) channels. Unfortunately, 3,4-DAP displays toxicity largely due to blood-brain-barrier (BBB) penetration. As a dual-action prodrug approach to cholinergic enhancement we have designed carbamate and amide conjugates of 3,4-DAP. The carbamate prodrug is intended to be a slowly reversible inhibitor of acetylcholinesterase (AChE) along the lines of the stigmines thereby allowing increased persistence of released acetylcholine within the synaptic cleft. As a secondary activity, cleavage of the carbamate prodrug by AChE will afford the localized release of 3,4-DAP, which in turn, will enhance the pre-synaptic release of additional acetylcholine. Being a competitive inhibitor with respect to acetylcholine, the activity of the prodrug will be greatest at the synaptic junctions most depleted of acetylcholine. Here we report upon the synthesis and biochemical characterization of three new classes of prodrugs intended to limit previously reported stability and toxicity issues. Of the prodrugs examined, compound 32, demonstrated the most clinically relevant half-life of 2.76 h, while selectively inhibiting AChE over butyrylcholinesterase-a plasma-based high activity esterase. Future in vivo studies could provide validation of prodrug 32 as a potential treatment against BoNT intoxication as well as other neuromuscular disorders. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2011.09.019

文献信息

• Acyloxybenzyl and Alkoxyalkyl Prodrugs of a Fosmidomycin Surrogate as Antimalarial and Antitubercular Agents
  作者：Charlotte Courtens、Martijn Risseeuw、Guy Caljon、Paul Cos、Serge Van Calenbergh

  DOI：10.1021/acsmedchemlett.8b00223

  日期：2018.10.11

  Two classes of prodrugs of a fosmidomycin surrogate were synthesized and investigated for their ability to inhibit in vitro growth of P. falciparum and M. tuberculosis. To this end, a novel efficient synthesis route was developed involving a cross metathesis reaction as a key step. Alkoxyalkyl prodrugs show decent antimalarial activities, but acyloxybenzyl prodrugs proved to be the most interesting

  合成了两类磷霉素的前药，并研究了它们抑制恶性疟原虫和结核分枝杆菌体外生长的能力。为此，开发了涉及交叉复分解反应作为关键步骤的新颖的有效合成途径。烷氧基烷基前药显示出良好的抗疟活性，但事实证明，酰氧基苄基前药是最令人感兴趣的，并显示出增强的抗疟和抗结核活性。最具活性的抗疟疾类似物显示出较低的纳摩尔IC 50值。
• Anti-HIV-Active Nucleoside Triphosphate Prodrugs
  作者：Xiao Jia、Dominique Schols、Chris Meier

  DOI：10.1021/acs.jmedchem.0c00271

  日期：2020.6.11

  We disclose a study on nucleoside triphosphate (NTP) analogues in which the γ-phosphate is covalently modified by two different biodegradable masking units and d4T as nucleoside analogue that enable the delivery of d4TTP with high selectivity in phosphate buffer (pH 7.3) and by enzyme-triggered reactions in human CD4+ T-lymphocyte CEM cell extracts. This allows the bypass of all steps normally needed

  我们公开了一项关于核苷三磷酸酯（NTP）类似物的研究，其中γ-磷酸酯被两个不同的可生物降解的掩蔽单元和d4T进行了共价修饰，从而使d4TTP在磷酸盐缓冲液（pH 7.3）和酶中具有较高的选择性CD4 + T淋巴细胞CEM细胞提取物中触发的反应。这允许绕过细胞内磷酸化通常所需的所有步骤。这些Tri PPP将包含酰氧基苄基（AB；酯）或烷氧基羰氧基苄基（ACB；碳酸酯）与ACB部分结合的环核苷酸描述为NTP递送系统。这两个不同基团的引入导致通过化学水解，特别是通过细胞提取酶选择性地形成γ-（ACB）-d4TTP。γ-（AB）-d4TTP的裂解速度比γ-（ACB）-d4TTP更快。在抗病毒测定中，这些化合物在野生型CEM / O细胞中具有更强的抗HIV-1和HIV-2活性，更重要的是在缺乏胸苷激酶的CD4 + T细胞（CEM / TK –）中具有很高的活性。
• Nucleotide and oligonucleotide prodrugs
  申请人：Iyer P. Radhakrishnan

  公开号：US20070149462A1

  公开（公告）日：2007-06-28

  The present invention discloses compounds of formula (I): which exhibit antiviral properties. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject in need of anti-HBV treatment. The invention also relates to methods of treating a HBV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

  本发明揭示了具有以下式（I）的化合物：这些化合物具有抗病毒性能。本发明还涉及包含上述化合物的药物组合物，用于给需要抗乙型肝炎治疗的受试者使用。该发明还涉及通过给予包含本发明化合物的药物组合物来治疗受试者的HBV感染的方法。
• Cellular Protection of SNAP-25 against Botulinum Neurotoxin/A: Inhibition of Thioredoxin Reductase through a Suicide Substrate Mechanism
  作者：Hajime Seki、Song Xue、Sabine Pellett、Peter Šilhár、Eric A. Johnson、Kim D. Janda

  DOI：10.1021/jacs.5b12929

  日期：2016.5.4

  attempts to ablate BoNT/A intoxication have sought to either nullify cellular toxin entry or critical biochemical junctions found within its intricate mechanism of action. In these regards, reports have surfaced of nonpeptidic small molecule inhibitors, but few have demonstrated efficacy in neutralizing cellular toxicity, a key prerequisite before rodent lethality studies can be initiated. On the basis

  肉毒杆菌神经毒素（BoNT）是人类已知的最致命的毒素之一。它们由七种血清型组成，其中 BoNT/A 是最致命的；然而，目前尚无批准的治疗药物中毒的方法，甚至还没有进入临床试验的治疗方法。肉毒杆菌的神经毒性最终是通过轻链 (LC) 蛋白酶 SNARE 蛋白裂解导致神经递质释放丧失来控制的。消除 BoNT/A 中毒的药理学尝试试图消除细胞毒素的进入或消除其复杂作用机制中发现的关键生化连接。在这方面，已有非肽类小分子抑制剂的报道浮出水面，但很少有报道显示出中和细胞毒性的功效，这是启动啮齿动物致死性研究之前的一个关键先决条件。基于我们在 BoNT/A 细胞检测活动中发现的先导化合物，我们研究了基于结构活性关系 (SAR) 基础的 N-羟基琥珀酰亚胺抑制剂家族。理论上，源自该 SAR 活动的分子是蛋白酶抑制剂。然而，这一主张在广泛的动力学分析的基础上被推翻了。出乎意料的是，抑制剂数据指向硫氧还蛋白还原酶
• [EN] PRODRUGS OF HYDROXAMATE-BASED GCPII INHIBITORS<br/>[FR] PROMÉDICAMENTS D'INHIBITEURS DE GCPII À BASE D'HYDROXAMATE
  申请人：UNIV JOHNS HOPKINS

  公开号：WO2018094334A1

  公开（公告）日：2018-05-24

  Prodrugs of hydroxamate-based GCPII inhibitors and methods of their use for treating a disease or condition are disclosed.

  本发明揭示了羟肟基GCPII抑制剂的前药及其用于治疗疾病或病况的方法。